Focused On-demand Library for Phenylalanine--tRNA ligase beta subunit

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.

We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Our partner Reaxense helps in synthesizing and delivering these compounds.

Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.

Our top-notch dedicated system is used to design specialised libraries for enzymes.

Fig. 1. The sreening workflow of Receptor.AI

The method includes detailed molecular simulations of the catalytic and allosteric binding pockets, along with ensemble virtual screening that considers their conformational flexibility. In the design of modulators, structural changes induced by reaction intermediates are taken into account to enhance activity and selectivity.

Our library distinguishes itself through several key aspects:

The Receptor.AI platform integrates all available data about the target protein, including past experiments, literature data, known ligands, structural information and more. This consolidated approach maximises the probability of prioritising highly relevant compounds.
The platform uses sophisticated molecular simulations to identify possible binding sites so that the compounds in the focused library are suitable for discovering allosteric inhibitors and the binders for cryptic pockets.
The platform integrates over 50 highly customisable AI models, which are thoroughly tested and validated on a multitude of commercial drug discovery programs and research projects. It is designed to be efficient, reliable and accurate. All this power is utilised when producing the focused libraries.
In addition to producing the focused libraries, Receptor.AI provides services and end-to-end solutions at every stage of preclinical drug discovery. The pricing model is success-based, which reduces your risks and leverages the mutual benefits of the project's success.

partner

Reaxense

upacc

Q9NSD9

UPID:

SYFB_HUMAN

Alternative names:

Phenylalanyl-tRNA synthetase beta subunit

Alternative UPACC:

Q9NSD9; B4DFM0; O95708; Q4ZFX1; Q57ZJ5; Q9NZZ6

Background:

The Phenylalanine--tRNA ligase beta subunit, also known as the Phenylalanyl-tRNA synthetase beta subunit, plays a crucial role in protein synthesis by attaching phenylalanine to its corresponding tRNA. This process is vital for the accurate translation of mRNA into protein, ensuring that proteins are correctly assembled with the appropriate amino acids.

Therapeutic significance:

Understanding the role of Phenylalanine--tRNA ligase beta subunit could open doors to potential therapeutic strategies. Its direct involvement in Rajab interstitial lung disease with brain calcifications 1, a severe neurodevelopmental disorder, highlights its significance in human health and disease. Targeting this protein could offer new avenues for treating or managing this debilitating condition.